

A circular inset showing a microscopic view of various cells, likely from a bone marrow smear, with a teal bookmark icon at the top right.

Reshaping **HIGHER-RISK MDS** **PATIENT-CENTERED** **CARE** with Emergence of Novel Evidence and Clinical Trials

IN-PERSON + VIRTUAL
SATELLITE SYMPOSIUM

SATURDAY, JUNE 4, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CO-CHAIRS

Naval G. Daver, MD

Guillermo Garcia-Manero, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

WELCOME

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Reshaping Higher-Risk MDS Patient-Centered Care with Emergence of Novel Evidence and Clinical Trials**.

This satellite symposium will bring together renowned experts in myelodysplastic syndromes (MDS) who will review the latest data regarding risk stratification and emerging treatment approaches for managing patients with higher-risk MDS. The format will include a review of pertinent clinical scenarios and provide an overview of risk stratification methods, novel biomarkers, and progression to acute myeloid leukemia; assessment for transplant eligibility; selection of subsequent-line therapy and emerging combination treatment approaches; and management of adverse events for patients with higher-risk MDS.

In working together with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved in the care of patients with higher-risk MDS.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you care for your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope that you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Naval G. Daver, MD

Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Guillermo Garcia-Manero, MD

Professor
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

6:30 PM	Registration & Dinner	
7:00 PM	Welcome, Introductions, and Pre-Session Survey	Naval G. Daver, MD
7:10 PM	Applying Risk Adapted Approaches to MDS Management: Molecular Markers and Classifications	Uma Borate, MD, MS
7:25 PM	Emerging Treatment Landscape of HR-MDS: Clinical Updates and Evolving Strategies	Naval G. Daver, MD
7:45 PM	Case Discussion: Integrating Recent Data and Emerging Strategies into Clinical Practice	Guillermo Garcia-Manero, MD
8:20 PM	Improving Patient QoL and AE Management in High-Risk MDS	Jacqueline S. Garcia, MD
8:40 PM	Looking to the Future: Discussion and Q&A with the Audience	Guillermo Garcia-Manero, MD
8:55 PM	Conclusions, Post-Session Survey, and Final Thoughts	Guillermo Garcia-Manero, MD
9:00 PM	Adjourn	

Upcoming PER® Conferences

2022

●	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
●	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
●	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
●	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
●	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
●	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
●	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
●	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
●	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
●	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10



Virtual Conference



In-Person + Virtual Conference

ACTIVITY OVERVIEW

Target Audience

This educational activity is directed toward medical oncologists, hematologists, radiation oncologists, advanced practitioners, and other oncology health care practitioners.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain the criteria for MDS diagnosis, as well as available tools for its classification and risk stratification
- Review endpoints utilized in recent clinical trials that have changed treatment of high-risk MDS
- Discuss unmet clinical needs in patients with high-risk MDS and the rationale for emerging therapies and combination strategies in patients with MDS
- Report the efficacy and safety profiles for current and emerging approaches for the care of patients with higher-risk MDS

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER[®] website by 12 PM EDT on Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/hr22mds-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/hr22mds-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 4, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource[®], LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource[®], LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Curis, Inc., Gilead Sciences, Inc., and Novartis Pharmaceuticals Corporation.

Thank you for attending **Reshaping Higher-Risk MDS Patient-Centered Care with Emergence of Novel Evidence and Clinical Trials!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.

ACTIVITY OVERVIEW

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Other
Uma Borate, MD, MS	AbbVie, Incyte, Jazz, Pfizer		Advisory board: AbbVie, Genentech, Agios, Novartis, Blueprint, Astellas, Takeda
Naval G. Daver, MD	Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Hanmi, Trovogene FATE Therapeutics, Novimmune, Glycomimetics	Daichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, Agios	
Jacqueline S. Garcia, MD	AbbVie, Genentech, AstraZeneca, Pfizer, Prelude	AbbVie, Genentech, Astellas	
Guillermo Garcia-Manero, MD	BMS, Astex, Novartis, AbbVie, Genentech, APR, Curis, Gilead		

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.


The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

PER® complies with all applicable laws, rules, and regulations, and, as such, we may be required to collect information on transfer of value provided to health care professionals or health care organizations.

Experience
the new
gotoper.com



Streamlining
education
for the busy
clinician



Program Co-Chairs

**Naval G. Daver, MD**

Associate Professor

Department of Leukemia, Division of Cancer Medicine

The University of Texas MD Anderson Cancer Center

Houston, TX

Naval G. Daver, MD, is an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC). He completed medical school at Grant Medical College and Sir J. J. Group of Hospitals, Mumbai, followed by a residency and fellowship in hematology-oncology at the Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials. This research centers on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML; evaluating novel combinations of targeted, immune, and cytotoxic agents; and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies and immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis; he is leading a number trials at MDACC.

Dr Daver has published more than 225 peer-reviewed manuscripts and is on the editorial board of numerous hematology-specific journals. He has also authored numerous abstracts at national and international conferences.

**Guillermo Garcia-Manero, MD**

Professor

Chief, Section of Myelodysplastic Syndromes

Deputy Chair, Translational Research

Department of Leukemia

The University of Texas MD Anderson Cancer Center

Houston, TX

Guillermo Garcia-Manero, MD, is the Dr Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC). He also is the chief of the section of myelodysplastic syndromes (MDS), vice chairman for translational research, leader of the MDS and acute myeloid leukemia (AML) Moon Shot program, and program director of the Leukemia Fellowship Program. He also is chair of the faculty senate of MDACC.

Dr Garcia-Manero received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, United Kingdom. He performed his internship and residency in internal medicine at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. He completed a fellowship in hematology and medical oncology at the Cardeza Foundation for Hematologic Research, the Sidney Kimmel Cancer Center, and the Thomas Jefferson University Hospital, where he served as chief fellow. In 1999, he became assistant professor in the Department of Leukemia at MDACC.

Dr Garcia-Manero's work has been funded by the National Institutes of Health, the US Department of Defense, the Cancer Prevention & Research Institute of Texas, and the MDS/AML Moon Shot project. He currently is the principal investigator (PI) or co-PI on over 25 active clinical trials focusing on AML and MDS. He has received several significant awards at MDACC, such as the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research.

FACULTY



Uma Borate, MD, MS

Clinical Associate Professor

Division of Hematology

The Ohio State University Comprehensive Cancer Center-James
Columbus, OH

Uma Borate, MD, MS, is a hematologist specializing in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and clonal cytopenias of unknown significance. She serves as an associate professor in the division of hematology at The Ohio State University and as the acute leukemia research disease group leader. Her clinical and translational research focus is on novel therapeutics in myeloid diseases, with a special focus in disease progression from cytopenia and early-stage MDS to AML. She is the principal investigator for numerous investigator-initiated clinical trials based on laboratory science, studying novel combinations of targeted therapies for myeloid malignancies. She is also the national lead and site investigator for several early-phase, industry-supported MDS and AML studies in both upfront and relapsed/refractory disease.

Dr Borate has pioneered a myeloid malignancy predisposition clinic focusing on clinical care and research in patients at high risk for myeloid malignancies due to predisposing hereditary germline mutations and acquired mutations. She is involved in developing several protocols for the National Cancer Institute cooperative groups in MDS and AML and the recently created MPN group.



Jacqueline S. Garcia, MD

Physician

Dana-Farber Cancer Center

Assistant Professor of Medicine

Harvard Medical School

Boston, MA

Jacqueline S. Garcia, MD, is an assistant professor of medicine at Harvard Medical School. She is a clinical/translational investigator in the adult leukemia program at the Dana-Farber Cancer Institute and an attending physician at the Brigham & Women's Hospital. She graduated from the University of Illinois at Chicago College of Medicine and completed her internship and residency training in internal medicine at the University of Chicago and hematology and oncology fellowship training at Stanford University.

Dr Garcia's research focus is on the design and execution of scientifically-based, early phase clinical and proof-of-concept studies in advanced myeloid malignancies, including myelodysplastic syndromes (MDS), myelofibrosis, and acute myeloid leukemia (AML). Much of her research centers on identifying novel therapeutic opportunities to leverage the antiapoptotic pathway in chemoresistant leukemia. She is the overall principal investigator (PI) of several investigator-initiated clinical studies and is the site PI for several industrially-sponsored studies for patients with AML, MDS, and advanced myelofibrosis. Her research has received support from the National Institutes of Health/National Cancer Institute, the Leukemia and Lymphoma Society, and the Conquer Cancer Foundation.



ASCO Direct[™] HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER[®]
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS[®] LIVE IN NYC**

**40th Annual
CFS[®]**
Chemotherapy Foundation
SYMPOSIUM
Innovative Cancer Therapy for Tomorrow[®]

**SAVE
THE
DATE!**

NOVEMBER 9 – 11, 2022
New York Marriott Marquis • New York, NY
In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit[™].

- 100** EXPERT FACULTY MEMBERS
- 25** TUMOR TYPES
- 3** DAYS
- 1** MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER[®]
Physicians'
Education
Resource, LLC
gotoper.com